Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Corporate Update on August 13
核心洞察
Capricor Therapeutics will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026.
Management will host a conference call and webcast at 4:30 p.m. ET the same day to discuss results and provide a recent corporate update.
The company's lead candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (搜索) (DMD).
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing cell and exosome-based therapeutics for rare diseases, announced that it will release its financial results for the second quarter ended June 30, 2026, after the market close on Thursday, August 13, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day to discuss the results and provide a recent corporate update.
The conference call, titled "Capricor Therapeutics Second Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast," will be accessible via toll-free dial-in at 1-800-717-1738, internationally at 1-646-307-1865, using Conference ID 91880. Participants may also use the Call me™ link for instant telephone access. A replay of the webcast will be available shortly after the conclusion of the live event in the Investors section of the company's website at www.capricor.com.
Lead Product Candidate: Deramiocel
Capricor's lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (搜索) (DMD). According to the company, Deramiocel has been shown in clinical studies to preserve cardiac and skeletal muscle function. Deramiocel remains an investigational candidate and has not been approved for commercial use in any indication.
StealthX Exosome Platform
Beyond Deramiocel, Capricor is advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. The StealthX vaccine is also an investigational candidate and has not been approved for commercial use in any indication.
Corporate and Regulatory Context
The company's forward-looking statements note ongoing litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute and Capricor's ability to commercialize Deramiocel independent of its existing distribution agreement. Capricor cautions that actual results or events may differ materially from those indicated by forward-looking statements, with additional risk factors detailed in its Annual Report on Form 10-K for the year ended December 31, 2025, filed March 17, 2026, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed May 13, 2026.